116 related articles for article (PubMed ID: 32491846)
1. Tetrazine-TCO Ligation: A Potential Simple Approach to Improve Tumor Uptake through Enhanced Blood Circulation.
Wang M; Wang H; Niu CQ; Zhang T; Wu Z; Li Z
Bioconjug Chem; 2020 Jul; 31(7):1795-1803. PubMed ID: 32491846
[TBL] [Abstract][Full Text] [Related]
2. Conformationally Strained trans-Cyclooctene (sTCO) Enables the Rapid Construction of (18)F-PET Probes via Tetrazine Ligation.
Wang M; Svatunek D; Rohlfing K; Liu Y; Wang H; Giglio B; Yuan H; Wu Z; Li Z; Fox J
Theranostics; 2016; 6(6):887-95. PubMed ID: 27162558
[TBL] [Abstract][Full Text] [Related]
3. Improved metabolic stability for 18F PET probes rapidly constructed via tetrazine trans-cyclooctene ligation.
Selvaraj R; Giglio B; Liu S; Wang H; Wang M; Yuan H; Chintala SR; Yap LP; Conti PS; Fox JM; Li Z
Bioconjug Chem; 2015 Mar; 26(3):435-42. PubMed ID: 25679331
[TBL] [Abstract][Full Text] [Related]
4. An Efficient Method for Labeling Single Domain Antibody Fragments with
Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
[TBL] [Abstract][Full Text] [Related]
5. Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
Ruivo E; Adhikari K; Elvas F; Fissers J; Vangestel C; Staelens S; Stroobants S; Van der Veken P; Wyffels L; Augustyns K
Nucl Med Biol; 2019; 76-77():36-42. PubMed ID: 31707309
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain.
Wyffels L; Thomae D; Waldron AM; Fissers J; Dedeurwaerdere S; Van der Veken P; Joossens J; Stroobants S; Augustyns K; Staelens S
Nucl Med Biol; 2014 Jul; 41(6):513-23. PubMed ID: 24768149
[TBL] [Abstract][Full Text] [Related]
7. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
8. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
9. Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody.
Rossin R; Läppchen T; van den Bosch SM; Laforest R; Robillard MS
J Nucl Med; 2013 Nov; 54(11):1989-95. PubMed ID: 24092936
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Organo [
Otaru S; Imlimthan S; Sarparanta M; Helariutta K; Wähälä K; Airaksinen AJ
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156020
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Structurally Diverse
Adhikari K; Dewulf J; Vangestel C; Van der Veken P; Stroobants S; Elvas F; Augustyns K
ACS Omega; 2023 Oct; 8(41):38252-38262. PubMed ID: 37867688
[No Abstract] [Full Text] [Related]
12. Improving Tumor-to-Background Contrast through Hydrophilic Tetrazines: The Construction of
Feng H; Zhang H; Wang M; Vannam R; Wang H; Yan X; Ouyang W; Jia X; Fox JM; Li Z
Chemistry; 2020 Apr; 26(21):4690-4694. PubMed ID: 32030822
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry.
Hou S; Choi JS; Garcia MA; Xing Y; Chen KJ; Chen YM; Jiang ZK; Ro T; Wu L; Stout DB; Tomlinson JS; Wang H; Chen K; Tseng HR; Lin WY
ACS Nano; 2016 Jan; 10(1):1417-24. PubMed ID: 26731174
[TBL] [Abstract][Full Text] [Related]
14. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
15. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
16. Diabody Pretargeting with Click Chemistry In Vivo.
van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
[TBL] [Abstract][Full Text] [Related]
17. Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue.
Goos JACM; Davydova M; Dilling TR; Cho A; Cornejo MA; Gupta A; Price WS; Puttick S; Whittaker MR; Quinn JF; Davis TP; Lewis JS
Nucl Med Biol; 2020; 84-85():63-72. PubMed ID: 32135473
[TBL] [Abstract][Full Text] [Related]
18.
Stéen EJL; Jørgensen JT; Johann K; Nørregaard K; Sohr B; Svatunek D; Birke A; Shalgunov V; Edem PE; Rossin R; Seidl C; Schmid F; Robillard MS; Kristensen JL; Mikula H; Barz M; Kjær A; Herth MM
ACS Nano; 2020 Jan; 14(1):568-584. PubMed ID: 31820928
[TBL] [Abstract][Full Text] [Related]
19. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
20. A 99mTc-Labelled Tetrazine for Bioorthogonal Chemistry. Synthesis and Biodistribution Studies with Small Molecule trans-Cyclooctene Derivatives.
Vito A; Alarabi H; Czorny S; Beiraghi O; Kent J; Janzen N; Genady AR; Al-Karmi SA; Rathmann S; Naperstkow Z; Blacker M; Llano L; Berti PJ; Valliant JF
PLoS One; 2016; 11(12):e0167425. PubMed ID: 27936007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
